Advances in Pneumococcal Vaccines: Efficacy, Implementation, and Coverage
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines and Public Health".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 393
Special Issue Editor
2. Servicio de Microbiologia, Hospital Universitario Donostia, Paseo Dr Beguiristain s/n, 20014 Donostia-San Sebastián, Spain
Interests: respiratory infections; pneumococcal pneumonia; pneumococcal vaccines; lung microbiome
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pneumococcal disease is a vaccine-preventable disease that causes mortality, especially in children under the age of 5 years and the elderly. Pneumococcal vaccines (PCVs) have altered the epidemiology of pneumococcal invasive and non-invasive diseases. In vaccinated individuals, infections caused by vaccine serotypes have decreased, and the decline in carriage of these vaccine serotypes has led to herd protection in unvaccinated populations. However, these results have been overshadowed by the emergence and spread of non-vaccine serotypes, which threaten the effectiveness of capsular-based vaccines. Implementation strategies vary, with some countries using phased rollouts based on disease burden and healthcare readiness. Key barriers to broader coverage include financing challenges, competing health priorities, and logistical constraints. Achieving high and sustainable PCV coverage requires closing implementation gaps and maintaining robust disease monitoring to maximize vaccine impact. This Special Issue will provide an opportunity to examine the commercialization of new PCVs covering more serotypes and evaluate methods for closing implementation gaps and maintaining robust disease monitoring.
Dr. Jose María Marimón
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pneumococcal conjugate vaccines
- pneumococcal diseases
- streptococcus pneumoniae serotypes
- serotype replacement
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
